We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Spectral Medical Inc.
An SI Board Since October 2011
Posts SubjectMarks Bans Symbol
351 9 0 EDTXF
Emcee:  Sultan Type:  Unmoderated
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada . More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

For further information please visit
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
351Spectral Medical Announces New Chief Financial Officer Wednesday
350dialco.caSultan-July 11
349Trump aims to shake up kidney care market politico.comSultan-July 9
348Corporate Presentation renmarkfinancial.comSultan-July 4
347Cappuccino with Claudio Ronco: youtu.beSultan-June 24
346Why Dialysis Is Heading Home carecentrix.comSultan-May 24
345AGM . June 4th Corporate presentations on June 5th & 6th at Renmark FinanciSultan-May 22
344The wind changed direction and the big river still flows: from EUPHRATES to TIGRSultan-May 21
343Cost savings, disruption threat pushing more providers into home dialysis moderSultan-May 12
342Spectral Announces First Quarter Results 9
341Q2 April Presentation spectraldx.comSultan-April 23
340April Presentation spectraldx.comSultan-April 8
339Spectral Announces Fourth Quarter and Fiscal 2018 Results 28
338Spectral Expands its Renal Replacement Therapy Development Program to Include thSultan-March 20
337Continues to move into new 52 week high.. Although volume has picked up, am sureSultan-February 25
336Volume and share price is beginning to perk up.. Just a matter of time; once agaSultan-February 22
335Spectral Announces First Orders of Its Proprietary CRRT Machine 21
334January Presentation spectraldx.comSultan-February 19
333Spectral Announces Approval of Tigris Trial by the US FDA TORONTO, Feb. 19, 201Sultan-February 19
332Latest Update by the company.. What happens next.. Targeted therapy for septicSultan-January 18
331EUPHRATES Trial Publication estor.itSultan-January 2
330Spectral to Attend the 37th Annual J.P. Morgan Healthcare Conference TORONTO, DSultan-12/19/2018
329Spectral Announces Results of a Face-to-Face meeting with the U.S. FDA TORONTO,Sultan-12/17/2018
328Spectral Announces Publication of the post hoc analysis of EUPHRATES trial in InSultan-11/26/2018
327Spectral to enhance the Sales and Marketing team in Canada
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):